<DOC>
	<DOCNO>NCT01872546</DOCNO>
	<brief_summary>The expertise characterization transcriptomics profile lesional psoriatic skin availability innovative therapy patients.The investigator propose follow modification skin transcriptomics profile psoriatic patient successful Adalimumab biotherapy . Skin transcriptomics profile normal skin , psoriatic non lesional skin , psoriatic lesional skin biotherapy compare . The investigator focus modification cytokine `` signature '' skin lesion marker keratinocyte inflammation . The modification transcriptomics profile induce biotherapy correlate clinical response Psoriasis Area Severity Index .</brief_summary>
	<brief_title>Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients chronic plaque psoriasis involve least 10 % body surface area previous biotherapy . Adalimumab prescribe usual practice Patients present contraindication use Adalimumab : hypersensibility Adalimumab one excipients . Patients present evolutionary tuberculosis severe infection sepsis opportunist infection present patient one cardiac insufficiency moderate severe Patients anakinra abatacept current participation another study clinical research</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>